Your browser doesn't support javascript.
loading
Evidence for a novel neuronal mechanism driving Alzheimer's disease, upstream of amyloid.
Garcia Ratés, Sara; García-Ayllón, María-Salud; Falgàs, Neus; Brangman, Sharon A; Esiri, Margaret M; Coen, Clive W; Greenfield, Susan Adele.
Afiliación
  • Garcia Ratés S; Neuro-Bio Ltd, Building F5, Culham Campus, Abingdon, UK.
  • García-Ayllón MS; Unidad de Investigación, Hospital General Universitario de Elche, FISABIO, Elche, Spain.
  • Falgàs N; Instituto de Neurociencias de Alicante, Universidad Miguel Hernández-CSIC, Sant Joan d'Alacant, Spain.
  • Brangman SA; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.
  • Esiri MM; Alzheimer's disease and other cognitive disorders Unit, Hospital Clínic de Barcelona. Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Coen CW; Department of Geriatrics, Upstate Center of Excellence for Alzheimer's Disease, SUNY Upstate Medical University 750 East Adams Street, Syracuse, New York, USA.
  • Greenfield SA; Neuropathology Department, John Radcliffe Hospital, West Wing, Oxford University, Oxford, UK.
Alzheimers Dement ; 20(7): 5027-5034, 2024 07.
Article en En | MEDLINE | ID: mdl-38780014
ABSTRACT
This perspective offers an alternative to the amyloid hypothesis in the etiology of Alzheimer's disease (AD). We review evidence for a novel signaling mechanism based on a little-known peptide, T14. T14 could drive neurodegeneration as an aberrantly activated process of plasticity selective to interconnecting subcortical nuclei, the isodendritic core, where cell loss starts at the pre-symptomatic stages of the disease. Each of these cell groups has the capacity to form T14, which can stimulate production of p-Tau and ß-amyloid, suggestive of an upstream driver of neurodegeneration. Moreover, results in an animal AD model show that antagonism of T14 with a cyclated variant, NBP14, prevents formation of ß-amyloid, and restores cognitive function to that of wild-type counterparts. Any diagnostic and/or therapeutic strategy based on T14-NBP14 awaits validation in clinical trials. However, an understanding of this novel signaling system could bring much-needed fresh insights into the progression of cell loss underlying AD. HIGHLIGHTS The possible primary mechanism of neurodegeneration upstream of amyloid. Primary involvement of selectively vulnerable subcortical nuclei, isodendritic core. Bioactive peptide T14 trophic in development but toxic in context of mature brain. Potential for early-stage biomarker to detect Alzheimer's disease. Effective therapeutic halting neurodegeneration, validated already in 5XFAD mice.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Alzheimer Límite: Animals / Humans Idioma: En Revista: Alzheimers Dement Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Alzheimer Límite: Animals / Humans Idioma: En Revista: Alzheimers Dement Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos